- Folate Binding Protein (FBP) shown to be safe and immunogenic in its Phase 1 trial
- Phase 2a trial expected to initiate by year end
Cramer points to Gilead's pipeline for its problems.
Here's how to trade seven of the most active names.
The timing of Schwartz' exit is noteworthy given Galena's admission on Jan. 9 of a criminal investigation of the company by the federal prosecutors into the marketing of Abstral.
The Dow Jones index of blue-chip stocks climbed to within 19 points of the 20,000 milestone before sliding backward, while the Nasdaq dropped from a record opening of 5,499.